United States · Platforms & data · MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Target Lowered at Guggenheim

Detailed summary
Guggenheim dropped their price target on ArriVent BioPharma from $30.00 to $28.00 and set a "buy" rating for the company in a research report on Monday.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)




